Skip to main content

Advertisement

SpringerLink
Log in

How do you treat patients with myalgia who take statins?

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are safe and effective in lowering low-density lipoprotein cholesterol. As a result, they confer an all-cause mortality benefit across a wide range of patient groups. The utility of statins is limited by their adverse effects, including myalgias and rhabdomyolysis. These clinical events, plus other symptoms, constitute what is termed statin myopathy. This review summarizes current concepts of statin myopathy and presents strategies to minimize statinassociated myopathic complaints.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Murphy SA, Cannon CP, Wiviott SD, et al.: Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). Am J Cardiol 2007, 100:1047–1051.

    Article  PubMed  CAS  Google Scholar 

  2. Bruckert E, Hayem G, Dejager S, et al.: Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther 2005, 19:403–414.

    Article  PubMed  CAS  Google Scholar 

  3. Staffa JA, Chang J, Green L: Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002, 346:539–540.

    Article  PubMed  Google Scholar 

  4. Kashani A, Phillips CO, Foody JM, et al.: Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006, 114:2788–2797.

    Article  PubMed  CAS  Google Scholar 

  5. Ballantyne CM, Corsini A, Davidson MH, et al.: Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003, 163:553–564.

    Article  PubMed  CAS  Google Scholar 

  6. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7–22.

    Article  Google Scholar 

  7. Harper CR, Jacobson TA: The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007, 18:401–408.

    Article  PubMed  CAS  Google Scholar 

  8. Sewright KA, Clarkson PM, Thompson PD: Statin myopathy: incidence, risk factors, and pathophysiology. Curr Atheroscler Rep 2007, 9:389–396.

    Article  PubMed  CAS  Google Scholar 

  9. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al.; American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002, 40:567–572.

    Article  PubMed  Google Scholar 

  10. McKenney JM, Davidson MH, Jacobson TA, et al.; National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006, 97(Suppl 8A):89C–94C.

    Article  PubMed  CAS  Google Scholar 

  11. Thompson PD, Clarkson PM, Rosenson RS; The National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel. An assessment of statin safety by muscle experts. Am J Cardiol. 2006 97(Suppl 8A):69C–76C.

    Article  PubMed  CAS  Google Scholar 

  12. Sorokin AV, Duncan B, Panetta R, Thompson PD: Rhabdomyolysis associated with pomegranate juice consumption. Am J Cardiol 2006, 98:705–706.

    Article  PubMed  Google Scholar 

  13. Thompson PD, Clarkson P, Karas RH: Statin-associated myopathy. JAMA 2003, 289:1681–1690.

    Article  PubMed  CAS  Google Scholar 

  14. Goosen TC, Bauman JN, Davis JA, et al.: Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos 2007, 35:1315–1324.

    Article  PubMed  CAS  Google Scholar 

  15. Prueksaritanont T, Tang C, Qiu Y, et al.: Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002, 30:1280–1287.

    Article  PubMed  CAS  Google Scholar 

  16. Kyrklund C, Backman JT, Kivistö KT, et al.: Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 2001, 69:340–345.

    Article  PubMed  CAS  Google Scholar 

  17. Sirvent P, Mercier J, Lacampagne A: New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol 2008, 8:333–338.

    Article  PubMed  CAS  Google Scholar 

  18. Draeger A, Monastyrskaya K, Mohaupt M, et al.: Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 2006, 210:94–102.

    Article  PubMed  CAS  Google Scholar 

  19. Phillips PS, Haas RH, Bannykh S, et al.; Scripps Mercy Clinical Research Center: Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002, 137:581–585.

    PubMed  Google Scholar 

  20. Päivä H, Thelen KM, Van Coster R, et al.: High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005, 78:60–68.

    Article  PubMed  Google Scholar 

  21. Urso ML, Scrimgeour AG, Chen YW, et al.: Analysis of human skeletal muscle after 48 h immobilization reveals alterations in mRNA and protein for extracellular matrix components. J Appl Physiol 2006, 101:1136–1148.

    Article  PubMed  CAS  Google Scholar 

  22. Hanai J, Cao P, Tanksale P, et al.: The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest 2007, 117:3940–3951.

    PubMed  CAS  Google Scholar 

  23. Smogorzewski M: The myopathy of statins. J Ren Nutr 2005, 15:87–93.

    Article  PubMed  Google Scholar 

  24. Dirks AJ, Jones KM: Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol 2006, 291:C1208–C1212.

    Article  PubMed  CAS  Google Scholar 

  25. Rodriguez MC, MacDonald JR, Mahoney DJ, et al.: Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007, 35:235–242.

    Article  PubMed  CAS  Google Scholar 

  26. Schon EA, Bonilla E, DiMauro S: Mitochondrial DNA mutations and pathogenesis. J Bioenerg Biomembr 1997, 29:131–149.

    Article  PubMed  CAS  Google Scholar 

  27. Chariot P, Abadia R, Agnus D, et al.: Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med 1993, 94:109–110.

    Article  PubMed  CAS  Google Scholar 

  28. Thomas JE, Lee N, Thompson PD: Statins provoking MELAS syndrome. A case report. Eur Neurol 2007, 57:232–235.

    Article  PubMed  Google Scholar 

  29. Marcoff L, Thompson PD: The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007, 49:2231–2237.

    Article  PubMed  CAS  Google Scholar 

  30. Caso G, Kelly P, McNurlan MA, et al.: Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007, 99:1409–1412.

    Article  PubMed  CAS  Google Scholar 

  31. Young JM, Florkowski CM, Molyneux SL, et al.: Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol 2007, 100:1400–1403.

    Article  PubMed  CAS  Google Scholar 

  32. Thompsen J, Thompson PD: A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis 2006, 189:31–38.

    Article  PubMed  CAS  Google Scholar 

  33. Huang CF, Li TC, Lin CC, et al.: Efficacy of Monascus pupureus West rice on lowering lipid rations in hypercholesterolemic patients. Eur J Cardiovasc Prev Rehabil 2007, 14:438–440.

    Article  PubMed  Google Scholar 

  34. Juszczyk MA, Seip RL, Thompson PD: Decreasing LDL cholesterol and medication cost with every-other-day statin therapy. Prev Cardiol 2005, 8:197–199.

    Article  PubMed  Google Scholar 

  35. Backes JM, Venero CV, Gibson CA, et al.: Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother 2008, 42:341–346.

    Article  PubMed  CAS  Google Scholar 

  36. Gadarla M, Kearns A, Thompson PD: Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol 2008, 101:1747–1748.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Hartford Hospital, 80 Seymour Street, Hartford, CT, 06102, USA

    Paul D. Thompson

Authors
  1. Saadi A. Siddiqi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul D. Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul D. Thompson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Siddiqi, S.A., Thompson, P.D. How do you treat patients with myalgia who take statins?. Curr Atheroscler Rep 11, 9–14 (2009). https://doi.org/10.1007/s11883-009-0002-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-009-0002-1

Keywords

Search

Navigation